Cassava sciences reports full-year 2022 financial results and operating updates

Austin, texas, feb. 28, 2023 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a clinical-stage biotechnology company focused on alzheimer's disease, today announced financial results for the year ended december 31, 2022, and provided operating updates. simufilam is cassava sciences' oral drug candidate for the proposed treatment of alzheimer's disease dementia.
SAVA Ratings Summary
SAVA Quant Ranking